ReviewBiochemistry2025
Biochemistry of Heat Shock Proteins From Human Intracellular Protozoan Parasites as Diagnostic and Therapeutic Biomarkers.
Review in Biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The main protozoan parasites, including Plasmodium, Leishmania, Toxoplasma, and Trypanosoma, face significant environmental stress during their life cycles. To survive, they rely on heat shock proteins (Hsps), which play essential roles in protein folding, preventing aggregation, and stabilizing cellular pathways under stress. Due to their critical functions, parasite Hsps have emerged as promising drug targets and potential diagnostic biomarkers. Several studies have revealed structural and functional differences between parasite and human Hsps, making them attractive for selective drug targeting. However, challenges such as specificity and host toxicity remain obstacles in Hsp-targeted therapies. Additionally, several key questions remain unanswered: What unique adaptations allow parasite Hsps to function efficiently? How do they interact with other chaperone systems? What roles do they play in parasite virulence and host-pathogen interactions? Addressing these gaps will enhance our understanding of parasite biology and support the development of more effective therapeutic and diagnostic strategies. This review evaluates the current knowledge on parasite Hsps, their potential as drug targets, and approaches to overcome existing challenges. Gaining deeper insights into their mechanistic roles could lead to safer and more targeted interventions against protozoan infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.